Cas:6106-46-3 Scopolamine Methyl Nitrate manufacturer & supplier

Chemical Name:Scopolamine Methyl Nitrate

CAS.NO:6106-46-3

Synonyms:scopolamine methyl nitrate;(1R,2R,4S,5S,7s)-7-{[(2S)-3-Hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane nitrate;MFCD00078239;EINECS 228-065-2

Molecular Formula:C₁₈H₂₄N₂O₇

Molecular Weight:380.392

HS Code:

Physical and Chemical Properties:

Melting point:199ºC

Boiling point:460.3ºC at 760 mmHg

Density:1.31 g/cm3

Index of Refraction:-25 ° (C=1, H2O)

PSA:127.94000

Exact Mass:380.158356

LogP:1.30560

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 1544 6.1/PG 3

Packing Group:

Contact us for information like scopolamine methyl nitrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 228-065-2 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 228-065-2 Use and application,scopolamine methyl nitrate technical grade,usp/ep/jp grade.

Related News: Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. Scopolamine Methyl Nitrate manufacturer This is of vital important and underlies one of the most solid principles and regulations of modern pharmacy. Scopolamine Methyl Nitrate supplier This is of vital important and underlies one of the most solid principles and regulations of modern pharmacy. Scopolamine Methyl Nitrate vendor This is of vital important and underlies one of the most solid principles and regulations of modern pharmacy. Scopolamine Methyl Nitrate factory China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.